Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on ‘diabetes, pre-diabetes, and cardiovascular disease’ to assess eligibility for sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland

Tom Caparrotta; Luke Blackburn; Stuart McGurnaghan; John Chalmers; Robert Lindsay; Rory McCrimmon; John McKnight; Sarah Wild; John R Petrie; Sam  Philip; Paul McKeigue; David Webb; Naveed A. Sattar; Helen Colhoun

doi:10.2337/dc20-0120

Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on ‘diabetes, pre-diabetes, and cardiovascular disease’ to assess eligibility for sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland

Tom Caparrotta, Luke Blackburn, Stuart McGurnaghan, John Chalmers, Robert Lindsay, Rory McCrimmon, John McKnight, Sarah Wild, John R Petrie, Sam Philip, Paul McKeigue, David Webb, Naveed A. Sattar, Helen Colhoun

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Diabetes Care
Early online date	24 Jun 2020
DOIs	https://doi.org/10.2337/dc20-0120
Publication status	E-pub ahead of print - 24 Jun 2020

Access to Document

10.2337/dc20-0120

Prescribing paradigm shift_ Applying the 2019 European Society of Cardiology-led guidelines on diabetesAccepted author manuscript, 289 KB

David Webb
- Deanery of Clinical Sciences - UoE Honorary staff
- Centre for Cardiovascular Science
Person: Affiliated Independent Researcher

Cite this

Caparrotta, T., Blackburn, L., McGurnaghan, S., Chalmers, J., Lindsay, R., McCrimmon, R., McKnight, J., Wild, S., Petrie, J. R., Philip, S., McKeigue, P., Webb, D., Sattar, N. A., & Colhoun, H. (2020). Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on ‘diabetes, pre-diabetes, and cardiovascular disease’ to assess eligibility for sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland. Diabetes Care. Advance online publication. https://doi.org/10.2337/dc20-0120

Caparrotta, Tom ; Blackburn, Luke ; McGurnaghan, Stuart et al. / Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on ‘diabetes, pre-diabetes, and cardiovascular disease’ to assess eligibility for sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland. In: Diabetes Care. 2020.

@article{711ce77df30a4634ae9c7c132ad32002,

title = "Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on {\textquoteleft}diabetes, pre-diabetes, and cardiovascular disease{\textquoteright} to assess eligibility for sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland",

author = "Tom Caparrotta and Luke Blackburn and Stuart McGurnaghan and John Chalmers and Robert Lindsay and Rory McCrimmon and John McKnight and Sarah Wild and Petrie, {John R} and Sam Philip and Paul McKeigue and David Webb and Sattar, {Naveed A.} and Helen Colhoun",

year = "2020",

month = jun,

day = "24",

doi = "10.2337/dc20-0120",

language = "English",

journal = "Diabetes Care",

issn = "0149-5992",

publisher = "American Diabetes Association Inc.",

}

Caparrotta, T, Blackburn, L, McGurnaghan, S, Chalmers, J, Lindsay, R, McCrimmon, R, McKnight, J, Wild, S, Petrie, JR, Philip, S, McKeigue, P , Webb, D, Sattar, NA & Colhoun, H 2020, 'Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on ‘diabetes, pre-diabetes, and cardiovascular disease’ to assess eligibility for sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland', Diabetes Care. https://doi.org/10.2337/dc20-0120

Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on ‘diabetes, pre-diabetes, and cardiovascular disease’ to assess eligibility for sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland. / Caparrotta, Tom; Blackburn, Luke; McGurnaghan, Stuart et al.
In: Diabetes Care, 24.06.2020.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on ‘diabetes, pre-diabetes, and cardiovascular disease’ to assess eligibility for sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland

AU - Caparrotta, Tom

AU - Blackburn, Luke

AU - McGurnaghan, Stuart

AU - Chalmers, John

AU - Lindsay, Robert

AU - McCrimmon, Rory

AU - McKnight, John

AU - Wild, Sarah

AU - Petrie, John R

AU - Philip, Sam

AU - McKeigue, Paul

AU - Webb, David

AU - Sattar, Naveed A.

AU - Colhoun, Helen

PY - 2020/6/24

Y1 - 2020/6/24

U2 - 10.2337/dc20-0120

DO - 10.2337/dc20-0120

M3 - Article

SN - 0149-5992

JO - Diabetes Care

JF - Diabetes Care

ER -

Caparrotta T, Blackburn L, McGurnaghan S, Chalmers J, Lindsay R, McCrimmon R et al. Prescribing paradigm shift? Applying the 2019 European Society of Cardiology-led guidelines on ‘diabetes, pre-diabetes, and cardiovascular disease’ to assess eligibility for sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists as first-line monotherapy (or add-on to metformin monotherapy) in type 2 diabetes in Scotland. Diabetes Care. 2020 Jun 24. Epub 2020 Jun 24. doi: 10.2337/dc20-0120

Access to Document

Profiles

David Webb

Cite this